Creating Patient-Derived Tumor Models From Head and Neck Cancer To Study New Targeted Treatments and Biomarkers

What this Trial Is About

Researchers are collecting fresh tumor tissue from patients with head and neck cancer, either primary or recurrent, to develop patient-derived xenografts. These models represent different tumor subgroups and will be used to study the genetics and behavior of the tumors, including their response to new targeted therapies and resistance patterns. The study aims to create a biobank to support preclinical evaluation of treatments for head and neck cancer. Patients will undergo a tumor biopsy of at least 0.5 cm2 during surgery or endoscopy if there is enough tissue available and after their consent. The collected tumor samples will be used to establish in vivo xenograft models. This observational study does not involve experimental treatments but focuses on tissue collection and laboratory analysis over a long-term period. Participants clinical data including stage, grade, and treatment history will be gathered, along with follow-up information. Researchers will analyze tumor samples using genetic profiling and immunohistochemistry to identify biomarkers related to drug sensitivity and treatment resistance. The primary outcome involves biomarker identification on tumor samples over 10 years, with ongoing characterization using genetic techniques. This long-term observation supports future cancer therapy development and assessment.

Patient-derived Xenograft Models of Tumor From Patients With Head and Neck Cancer